Voyager Therapeutics, Inc. 8-K

What Happened Voyager Therapeutics (filed 8-K on April 21, 2026) announced that Chief Financial Officer Nathan Jorgensen, Ph.D., notified the company on April 15, 2026 that he will resign effective May 8, 2026 to pursue another opportunity. The company said his resignation is not due to any disagreement with Voyager. On April 20, 2026 the board appointed Robin Swartz to become principal financial officer and treasurer and appointed Amy Quinlan to become principal accounting officer, both effective as of May 8, 2026.

Key Details

• Dr. Nathan Jorgensen notified the company of his resignation on April 15, 2026; effective date (transition) is May 8, 2026.
• Board appointments made April 20, 2026: Robin Swartz (age 55) to principal financial officer and treasurer; Amy Quinlan (age 51) to principal accounting officer.
• Ms. Swartz has served as Voyager’s Chief Operating Officer and Chief Business Officer since November 2024 and held prior finance and operations roles at Sanofi Genzyme.
• Ms. Quinlan has been Voyager’s Vice President of Finance since January 2025 and previously served as VP Finance at Vor Biopharma; she is expected to enter Voyager’s standard indemnification agreement.

Why It Matters A CFO transition directly affects oversight of Voyager’s financial reporting, treasury and investor communications. The company promoted internal and experienced finance/operations leaders, which supports continuity in financial management and reporting. The filing notes no disagreement with the company, reducing near-term governance risk; the indemnification arrangement for the new principal accounting officer is standard and may cover legal costs related to service as an officer. Investors should watch for any changes in financial guidance, reporting cadence, or commentary tied to the leadership change in upcoming filings and communications.